First results from the phase III ALTTO trial (BIG 02-06; NCCTG 063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone.
Updates in the Treatment of Breast cancer Mohammad Jahanzeb, MD, FACP Professor of Clinical Medicine, Hematology-Oncology Director, UM Sylvester Deerfield.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
Presented By Eric Winer at 2014 ASCO Annual Meeting
